Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 373

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 373
---
earlier terminated by our board of directors, the 2023 Omnibus Plan will terminate on, and no further awards may be granted, after the
tenth (10th) anniversary of its effective date.

Termination
and Amendment of Plan

Our
board of directors or the Administrator may amend, alter, suspend, discontinue, or terminate the 2023 Omnibus Plan at any time, subject
to the following limitations:

    ●
    Our
    board of directors must approve any amendment to the 2023 Omnibus Plan if we determine such approval is required by prior action
    of our board of directors, applicable corporate law, or any other applicable law;

    ●
    Stockholders
    must approve any amendment to the 2023 Omnibus Plan, which may include an amendment to materially increase the number of shares reserved
    under the 2023 Omnibus Plan, if we determine that such approval is required by Section 16 of the Exchange Act, the Code, the listing
    requirements of any principal securities exchange or market on which the shares are then traded, or any other applicable law; and

    ●
    Stockholders
    must approve any amendment to the 2023 Omnibus Plan that would diminish the protections afforded by the participant award limits
    or repricing and backdating prohibitions.

Amendment,
Modification, Cancellation and Disgorgement of Awards

Subject
to the requirements of the 2023 Omnibus Plan, the Administrator may modify or amend any award or waive any restrictions or conditions
applicable to any award or the exercise of the award, or amend, modify, or cancel any terms and conditions applicable to any award, in
each case, by mutual agreement of the Administrator and the participant or any other person that may have an interest in the award, so
long as any such action does not increase the number of shares of common stock issuable under the 2023 Omnibus Plan.

We
do not need to obtain participant (or other interested party) consent for any such action (a) that is permitted pursuant to the adjustment
provisions of the 2023 Omnibus Plan; (b) to the extent we deem the action necessary to comply with any applicable law or the listing
requirements of any principal securities exchange or market on which our common stock is then traded; (c) to the extent we deem the action
is necessary to preserve favorable accounting or tax treatment of any award for us; or (d) to the